Vanguard Capital Management’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17M Buy
1,234,175
+7,103
+0.6% +$105K ﹤0.01% 2481
2026
Q2
$19.5M Buy
1,227,072
+103,361
+9% +$1.66M ﹤0.01% 2461
2026
Q1
$14.8M Buy
+1,123,711
New +$16.9M ﹤0.01% 2507

Other funds holding NPCE

Vanguard Capital Management's NPCE Position: Q3 2026 in Review

Vanguard Capital Management increased its Neuropace (NPCE) stake by 0.58% in Q3 2026, buying an estimated $105K and bringing the position to 1,234,175 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

Vanguard Capital Management first reported a position in NPCE in Q1 2026 and has held it in 3 quarters since. The position peaked at $19.5M in Q2 2026. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Vanguard Capital Management held 1,234,175 shares of Neuropace worth $17M as of Q3 2026.
  • Vanguard Capital Management bought 7,103 Neuropace shares in Q3 2026, an estimated $105K.
  • Neuropace made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2481 holding.
  • Vanguard Capital Management first reported a position in Neuropace in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Neuropace position peaked at $19.5M in Q2 2026.
  • 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.